InvestorsHub Logo
Followers 8
Posts 481
Boards Moderated 0
Alias Born 02/03/2021

Re: daemon57 post# 174896

Monday, 07/19/2021 4:19:47 PM

Monday, July 19, 2021 4:19:47 PM

Post# of 232965
Some shorts in twitter are honing in on Holly Kennedy's death in spite of LL treatment - almost suggesting (in 2nd tweet) as if the deterioration was accelerated because of LL.




It is an anecdotal case that did not work out. Does it make sense to point out one patient in order to undermine the net results of the trial? "We don't believe Nader" or "Nader would have twisted the results to make them appear positive" - those are different argument.

The article/PR has

“While these are only interim results at the 12-month point, our ability to rapidly monitor and identify patients [who] appear to respond to leronlimab using a single tube of blood is quite an encouraging finding,” Daniel Adams, Director of Clinical Research and Development, Creatv MicroTech, Inc., said in a press release.



Not all will respond and the trial is helping us filter the right patients; but the results are indicating a net positive outcome superior to SOC alone.

PS. I see that the trial is conducted alongside an SOC called Carboplatin. Does it mean that these trial patients were all at a stage where Chemotherapy is no longer possible?

Also, anyone know how many of the 30 patients got LL+ Carbo and how many got Placebo+Carbo?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News